Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopa…
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We…
Myasthenia gravis, an immune-mediated neurologic disorder, has for the past century been treated effectively with various immunotherapies, ranging from thymectomy to approved targeted agents.1,2 Th…
With changes to preclinical curricula, some medical schools have eliminated certain freestanding subject-based courses, such as histology and pathobiology.
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We…
Despite the potential for drug-price negotiation to help rein in spending, several provisions in the Inflation Reduction Act may limit Medicare’s new negotiating authority for…
With changes to preclinical curricula, some medical schools have eliminated certain freestanding subject-based courses, such as histology and pathobiology.
Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment. We carried out two 48-week, randomized,…
This report describes three cases of clade Ib MPXV infection in pregnant women (one in each trimester of gestation) with molecular and histopathological evidence of…
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell…
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer, an…
